Our Approach

Osteoporosis Research Ltd is a legal manufacturer for FRAX® and FRAXplus®

​

The FRAX® tool has been developed to evaluate fracture risk. It is based on individualised models that integrate the risks associated with clinical risk factors as well as bone mineral density (BMD) at the femoral neck.

​

FRAXplus®  allows you to modify a probability result derived from conventional FRAX estimates of probabilities of hip fracture and major osteoporotic fracture with knowledge of:

• Recency of osteoporotic fracture

• Higher than average exposure to oral glucocorticoids

• Information on trabecular bone score (TBS)

• Number of falls in the previous year

• Duration of Type 2 diabetes mellitus

• Concurrent information on lumbar spine BMD

• Hip axis length (HAL)

​